Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Protective factor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Protective factor. Displaying page 1 of 1.
    EudraCT Number: 2014-005401-20 Sponsor Protocol Number: CSLCT-BIO-03-97 Start Date*: 2015-01-30
    Sponsor Name:CSL Limited
    Full Title: An Open-label, Multi-centre Study to Assess the Efficacy and Safety of Biostate® in Patients With von Willebrand's Disease (VWD)
    Medical condition: Von Willebrand's disease (VWD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-000441-58 Sponsor Protocol Number: 08005DM-A Start Date*: 2009-01-22
    Sponsor Name:Belfast City Hospital
    Full Title: Investigation of the protective effects of keratinocyte growth factor (KGF) in a human lipopolysaccharide induced model of acute lung injury
    Medical condition: Acute lung injury
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018531-17 Sponsor Protocol Number: TRED012010 Start Date*: 2010-06-25
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: Effect of Tredaptive on serum lipoproteins, lipoproteins metabolism, oxidative stress and HDL antioxidant function.
    Medical condition: Hypercholesterolaemia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004042-42 Sponsor Protocol Number: DEER Start Date*: 2014-06-19
    Sponsor Name:King’s College London [...]
    1. King’s College London
    2. Guy's and St Thomas NHS Foundation Trust
    Full Title: A study to investigate the potential renoprotective role of sodium-glucose transporter-2 (SGLT-2) antagonist Dapagliflozin in Type 2 diabetic patients with diabetic nephropathy
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-000565-32 Sponsor Protocol Number: PRIDE Start Date*: 2023-04-27
    Sponsor Name:Klinikum der Universität München
    Full Title: PRIDE: A phase II a, open-label, multicenter study of radiochemotherapy with isotoxic dose escalation and protective VEGF inhibition using bevacizumab in the treatment of patients with first diagno...
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001103-31 Sponsor Protocol Number: AIT02-2001/DMID14-005 Start Date*: 2015-07-10
    Sponsor Name:Autoimmune Technologies, LLC
    Full Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled Assessment of the Safety and Protective Efficacy of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Healthy Adult Subjects wh...
    Medical condition: Influenza A infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016731-34 Sponsor Protocol Number: CRO1413 Start Date*: 2010-01-08
    Sponsor Name:Imperial College
    Full Title: Amino acid regimen and intravenous lipid composition in preterm parenteral nutrition: a randomised double blind controlled trial of Nutritional Evaluation and Optimisation in Neonates.
    Medical condition: Preterm birth
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036594 Premature birth LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021015-16 Sponsor Protocol Number: TFM-CL3-002 Start Date*: 2010-09-30
    Sponsor Name:Olympus France SAS
    Full Title: A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment with Trafermin 0.01% Spray in Patients with Diabetic Foot Ulcer of Neuropathic ...
    Medical condition: Wound closure rate of diabetic foot ulcers (DFUs) of neuropathic origin.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) DK (Completed) SE (Completed) DE (Completed) NL (Completed) HU (Completed) SK (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011175-70 Sponsor Protocol Number: 805 Start Date*: 2009-05-28
    Sponsor Name:Liverpool Heart and Chest Hospital
    Full Title: A randomised factorial trial of N-acetylcysteine prophylaxis and iso-osmolar versus low-osmolar contrast media on kidney function in patients at risk of contrast induced nephropathy following cardi...
    Medical condition: Contrast-induced nephropathy following cardiac catheterisation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010836 Contrast media reaction LLT
    12.1 10066973 Contrast media allergy LLT
    12.1 10029151 Nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-000946-24 Sponsor Protocol Number: 15-EI-0202 Start Date*: 2018-01-09
    Sponsor Name:National Eye Institute
    Full Title: Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated with Age-Related Macular Degeneration
    Medical condition: Geographic Atrophy Associated with Age-Related Macular Degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-021014-33 Sponsor Protocol Number: TFM-CL3-001 Start Date*: 2010-09-30
    Sponsor Name:Olympus France SAS
    Full Title: A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment with Trafermin 0.01% Spray in Patients with Diabetic Foot Ulcer of Neuropathic ...
    Medical condition: Wound closure rate of diabetic foot ulcers (DFUs) of neuropathic origin.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002690-35 Sponsor Protocol Number: OEV123 Start Date*: 2017-05-08
    Sponsor Name:Scandinavian Biopharma AB
    Full Title: A randomized, placebo-controlled phase IIb (OEV 123) study to evaluate safety, immunogenicity, diagnostic methodology, and estimate vaccine efficacy of an oral enterotoxigenic Escherichia coli (ET...
    Medical condition: Healthy voluteers (prevention of diarrheal disease due to infection with enterotoxigenic E. coli [ETEC])
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10054242 Escherichia coli infection LLT
    19.1 100000004862 10044552 Traveller's diarrhea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2012-004366-18 Sponsor Protocol Number: CNTO148UCO1001 Start Date*: 2013-07-30
    Sponsor Name:Janssen Biologics B.V.
    Full Title: A Phase 1b Open-Label Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human anti-TNFα Antibody, in Pediatric Subjects with Moderately to Severely Active ...
    Medical condition: Ulcerative Colitis in pediatric subjects
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) DE (Completed) NL (Ongoing) DK (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-000962-14 Sponsor Protocol Number: CCM-RNT-202101 Start Date*: 2021-07-02
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 07:16:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA